The seasonal COVID-19 spike, combined with rising cases of seasonal flu and RSV, brings what has been called a “tripledemic.” ...

Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution ...

“Younger children may have different symptoms (e.g., diarrhea ... and attempts to address the rise of FLiRT omicron variants ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

The latest coronavirus strain, XEC, makes up 17%. It is another descendant from the Omicron family, according to Yale ...

The XEC COVID-19 variant is poised to become the dominant variant worldwide. Now is a good time to get an updated COVID ...

At 6 weeks after infection, health care personnel who received vs those who did not receive subsequent doses of the original monovalent COVID-19 vaccine had a lower prevalence of symptoms. Health care ...

The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 ...

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...

Nirmatrelvir-ritonavir effectively lowers hospitalization rates and long COVID symptoms in non-hospitalized, high-risk patients with mild to moderate COVID-19.

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, ...